A functional TNFRSF5 gene variant is associated with risk of lymphoma

Blood

Volumn 111, Issue 8, 2008, Pages 4348-4354

  Skibola, Christine F ^a   Nieters, Alexandra ^b   Bracci, Paige M ^c   Curry, John D ^a   Agana, Luz ^a   Skibola, Danica R ^a   Hubbard, Alan ^a   Becker, Nikolaus ^b   Smith, Martyn T ^a   Holly, Elizabeth A ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; TNF RECEPTOR SUPERFAMILY MEMBER 5; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; CYTOSINE; LIPOPOLYSACCHARIDE; THYMINE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CASE CONTROL STUDY; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CONFIDENCE INTERVAL; DENDRITIC CELL; DRUG EFFECT; FOLLICULAR LYMPHOMA; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; RISK; SOLUBILITY;

ADULT; AGED; ANTIGENS, CD40; CD40 LIGAND; CONFIDENCE INTERVALS; CYTOSINE; DENDRITIC CELLS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPOPOLYSACCHARIDES; LYMPHOMA, FOLLICULAR; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; SOLUBILITY; THYMINE;

EID: 43249125511     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-09-112144     Document Type: Article

References (44)

1. Skibola CF. Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica. 2007;92: 960-969.
2. Huang JZ. Sanger WG, GreinerTC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood. 2002:99:2285-2290.
3. Kuppers R, Rajewsky K, Hansmann ML. Diffuse large cell lymphomas are derived from mature B cells carrying V region genes with a high load of somatic mutation and evidence of selection for antibody expression. Eur J Immunol. 1997;27: 1398-1405.
4. Marafioti T Hummel M, Anagnostopoulos I, Foss HD, Huhn D, Stein H. Classical Hodgkin's disease and follicular lymphoma originating from the same germinal center B cell. J Clin Oncol. 1999; 17:3804-3809.
5. Clark LB, Foy TM, Noelle RJ. CD40 and its li-gand. Adv Immunol. 1996;63:43-78.
6. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998:16: 111-135.
7. Mackey MR Barth RJ Jr, Noelle RJ. The role of CD40/CD154 interactions in the priming, differentiation, and effector function of helper and cyto- toxicTcells. J Leukoc Biol. 1998;63:418-428.
8. Tsuzuki M, Morishima I, Yoshida T, et al. Inverse correlation between soluble CD40 ligand and soluble CD40 is absent in patients with unstable angina. Heart Vessels. 2005;20:245-250.
9. Younes A, Snell V, Gonsoli U, et al. Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia. Br J Haematol. 1998;100:135-141.
10. Contin C, Pitard V, Itai T, Nagata S, Moreau JF. Dechanet-Merville J. Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha- converting enzyme: implications for CD40 signaling. J Biol Chem. 2003:278:32801-32809.
11. Matthies KM, Newman JL, HodzicA, Wingett DG. Differential regulation of soluble and membrane CD40L proteins in T cells. Cell Immunol. 2006; 241:47-58.
12. O'Connor BP, Gleeson MW, Noelle RJ, Erickson LD. The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease. Immunol Rev. 2003:194:61-76.
13. Fontana S, Moratto D. Mangal S, et al. Functional defects of dendritic cells in patients with CD40 deficiency. Blood. 2003:102:4099-4106.
14. Tomer Y, Concepcion E, Greenberg DA. AC/T single-nucleotide polymorphism in the region of the CD40 gene is associated with Graves' disease. Thyroid. 2002;12:1129-1135.
15. Jacobson EM, Concepcion E, Oashi T, Tomer Y. A Graves' disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathophysiology. Endocrinology. 2005;146:2684-2691.
16. Park JH, Chang HS, Park CS, et al. Association analysis of CD40 polymorphisms with asthma and the level of serum total IgE. Am J Respir Crit Care Med. 2007;175:775-782.
17. Jacobson EM, Huber AK, Akeno N, et al. ACD40 Kozak sequence polymorphism and susceptibility to antibody-mediated autoimmune conditions: the role of CD40 tissue-specific expression. Genes Immun. 2007;8:205-214.
18. Kozak M. Structural features in eukaryotic mRNAs that modulate the initiation of translation. J Biol Chem. 1991 ;266:19867-19870.
19. Kozak M. An analysis of vertebrate mRNA sequences: intimations of translational control. J Cell Biol. 1991;115:887-903.
20. Holly EA, Bracci PM. Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus- negative participants in San Francisco. Am J Epidemiol. 2003;158:316-327.
21. Holly EA, Lele C, Bracci PM. Hair-color products and risk for non-Hodgkin's lymphoma: a population-based study in the San Francisco bay area. Am J Public Health. 1998:88:1767-1773.
22. Holly EA, Lele C, Bracci PM, McGrath MS. Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol. 1999; 150:375-389.
23. Kamel OW. Holly EA, van de Rijn M, Lele C, Sah A. A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis. J Rheumatol. 1999;26:1676-1680.
24. Becker N, Deeg E, Nieters A. Population-based study of lymphoma in Germany: rationale, study design and first results. Leuk Res. 2004;28:713-724.
25. National Center for Biotechnology Information. Entrez SNP, Hap map database. http://www.ncbi.nlm.nih.gov/projects/SNP/. Accessed October 2004.
26. CHIP (Children's Hospital Informatics Program). http://snpper.chip.org/. SNPper. Accessed October 2004.
27. Skibola CF Bracci PM, Paynter RA, et al. Polymorphisms and haplotypes in the cytochrome P450 17A1, prolactin, and catechol-O-methyl-transferase genes and non-Hodgkin lymphoma risk. Cancer Epidemiol Biomarkers Prev. 2005: 14:2391-2401.
28. Fakhrai-Rad H, Pourmand N, Ronaghi M. Pyro-sequencing: an accurate detection platform for single nucleotide polymorphisms. Hum Mutat. 2002;19:479-485.
29. Zhao JH, Lissarrague S, Essioux L. Sham PC. GENECOUNTING: haplotype analysis with missing genotypes. Bioinformatics. 2002;18:1694-1695.
30. Alizadeh AA, Eisen MB. Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000:403: 503-511.
31. Bennett SR. Carbone FR, Karamalis F Flavell RA, Miller J F, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478-480.
32. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helperand a T-killer cell. Nature. 1998; 393:474-478.
33. Schoenberger SP, Toes RE. van der Voort El, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
34. Gaspal FM, McConnell FM, Kim MY, et al. The generation of thymus-independent germinal centers depends on CD40 but not on CD154, the T cell-derived CD40-ligand. Eur J Immunol. 2006; 36:1665-1673.
35. Xu J, Foy TM, Laman JD, et al. Mice deficient for the CD40 ligand. Immunity. 1994;1:423-431.
36. Ferrari S, Giliani S, Insalaco A, et al. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc Natl Acad Sci U S A. 2001 ;98:12614-12619.
37. Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Grit Rev Biochem Mol Biol. 2007;42:113-185.
38. van Kooten C, Gaillard C, Galizzi JR et al. B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release of soluble CD40. Eur J Immunol. 1994:24:787-792.
39. Contin C, Pitard V. Delmas Y, et al. Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients. Immunology. 2003;110:131-140.
40. Hock BD, McKenzie JL, Patton NW, et al. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer. 2006;106:2148-2157.
41. French RR, Taraban VY, Crowther GR. et al. Eradication of lymphoma by CDS T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood. 2007;109:4810-4815.
42. Schjetne KW, Fredriksen AB, Bogen B. Delivery of antigen to CD40 induces protective immune responses against tumors. J Immunol. 2007;178: 4169-4176.
43. Messmer D, Kipps TJ. CD 154 gene therapy for human B-cell malignancies. Ann N Y Acad Sci. 2005;1062:51-60.
44. Loskog A, Totterman TH. CD40L: a multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets. 2007;7:23-28.